Codexis Management

Management criteria checks 1/4

Codexis' CEO is Stephen Dilly, appointed in Aug 2022, has a tenure of 1.58 years. total yearly compensation is $5.89M, comprised of 4.7% salary and 95.3% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth $634.75K. The average tenure of the management team and the board of directors is 1.6 years and 3.3 years respectively.

Key information

Stephen Dilly

Chief executive officer

US$5.9m

Total compensation

CEO salary percentage4.7%
CEO tenure1.6yrs
CEO ownership0.3%
Management average tenure1.6yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Codexis, Inc.'s (NASDAQ:CDXS) Shares Leap 56% Yet They're Still Not Telling The Full Story

Dec 20
Codexis, Inc.'s (NASDAQ:CDXS) Shares Leap 56% Yet They're Still Not Telling The Full Story

What Does Codexis, Inc.'s (NASDAQ:CDXS) Share Price Indicate?

Dec 19
What Does Codexis, Inc.'s (NASDAQ:CDXS) Share Price Indicate?

Is Codexis (NASDAQ:CDXS) In A Good Position To Deliver On Growth Plans?

Nov 15
Is Codexis (NASDAQ:CDXS) In A Good Position To Deliver On Growth Plans?

Lacklustre Performance Is Driving Codexis, Inc.'s (NASDAQ:CDXS) Low P/S

Jun 28
Lacklustre Performance Is Driving Codexis, Inc.'s (NASDAQ:CDXS) Low P/S

Calculating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS)

Jun 07
Calculating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS)

At US$3.41, Is It Time To Put Codexis, Inc. (NASDAQ:CDXS) On Your Watch List?

May 09
At US$3.41, Is It Time To Put Codexis, Inc. (NASDAQ:CDXS) On Your Watch List?

Analysts Just Made A Major Revision To Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts

Feb 27
Analysts Just Made A Major Revision To Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts

We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn

Feb 25
We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn

Is Codexis, Inc. (NASDAQ:CDXS) Trading At A 28% Discount?

Nov 05
Is Codexis, Inc. (NASDAQ:CDXS) Trading At A 28% Discount?

Codexis appoints Kevin Norrett as chief operating officer

Oct 03

We Think Codexis (NASDAQ:CDXS) Can Afford To Drive Business Growth

Aug 23
We Think Codexis (NASDAQ:CDXS) Can Afford To Drive Business Growth

Analysts Have Just Cut Their Codexis, Inc. (NASDAQ:CDXS) Revenue Estimates By 10%

Jul 28
Analysts Have Just Cut Their Codexis, Inc. (NASDAQ:CDXS) Revenue Estimates By 10%

Codexis: Profitability, Return On Capital Are Persistent Headwinds Looking Ahead

Jul 27

Codexis gets new executive chief

Jul 18

Are Investors Undervaluing Codexis, Inc. (NASDAQ:CDXS) By 35%?

Jul 06
Are Investors Undervaluing Codexis, Inc. (NASDAQ:CDXS) By 35%?

Why Codexis, Inc. (NASDAQ:CDXS) Could Be Worth Watching

May 10
Why Codexis, Inc. (NASDAQ:CDXS) Could Be Worth Watching

Codexis: A Company Rooting Itself In A Blossoming Market

Apr 18

We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn

Apr 09
We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn

Does This Valuation Of Codexis, Inc. (NASDAQ:CDXS) Imply Investors Are Overpaying?

Mar 14
Does This Valuation Of Codexis, Inc. (NASDAQ:CDXS) Imply Investors Are Overpaying?

CEO Compensation Analysis

How has Stephen Dilly's remuneration changed compared to Codexis's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$76m

Sep 30 2023n/an/a

-US$82m

Jun 30 2023n/an/a

-US$57m

Mar 31 2023n/an/a

-US$48m

Dec 31 2022US$6mUS$279k

-US$34m

Sep 30 2022n/an/a

-US$31m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$21m

Dec 31 2021US$175kn/a

-US$21m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

-US$23m

Mar 31 2021n/an/a

-US$25m

Dec 31 2020US$241kn/a

-US$24m

Compensation vs Market: Stephen's total compensation ($USD5.89M) is above average for companies of similar size in the US market ($USD1.47M).

Compensation vs Earnings: Stephen's compensation has increased whilst the company is unprofitable.


CEO

Stephen Dilly (63 yo)

1.6yrs

Tenure

US$5,893,151

Compensation

Dr. Stephen George Dilly, M.B.B.S, Ph D., serves as Independent Director of Codexis, Inc. since June 16, 2020. He serves as Director at ImmunoMolecular Therapeutics, Inc since February 2020.Dr. Dilly serv...


Leadership Team

NamePositionTenureCompensationOwnership
Stephen Dilly
President1.6yrsUS$5.89m0.26%
$ 634.7k
Kevin Norrett
Chief Operating Officer1.4yrsUS$2.62m0.21%
$ 525.1k
Margaret Fitzgerald
Chief Legal and Compliance Officer1.3yrsUS$2.18m0.049%
$ 121.4k
Sriram Ryali
Chief Financial Officer1.2yrsno data0.18%
$ 430.8k
Carrie McKim
Director of Investor Relationsno datano datano data
Karen Frechou-Armijo
Senior VP & Head of Human Resources2.3yrsno datano data
Stefan Lutz
Senior Vice President of Research3.8yrsno datano data
Robert Sato
Senior Vice President of Pharmaceutical Development3.7yrsno datano data

1.6yrs

Average Tenure

51yo

Average Age

Experienced Management: CDXS's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Stephen Dilly
President3.8yrsUS$5.89m0.26%
$ 634.7k
H. Parker
Independent Director1.3yrsUS$203.47k0.10%
$ 253.0k
John M. Maraganore
Member of Strategic Advisory Boardless than a yearno datano data
David Smith
Independent Director8yrsUS$194.99k0.18%
$ 429.9k
Dennis Wolf
Independent Director16.3yrsUS$189.99k0.11%
$ 268.0k
Rahul Singhvi
Independent Director1.4yrsUS$217.96k0.094%
$ 230.2k
James Lalonde
Member of Strategic Advisory Boardless than a yearUS$1.02mno data
Masad Damha
Member of Strategic Advisory Boardless than a yearno datano data
Byron Dorgan
Independent Chairman13.1yrsUS$221.66k0.28%
$ 675.2k
Alison Moore
Independent Director3.8yrsUS$189.99k0.098%
$ 239.3k
Jennifer Aaker
Independent Director3.6yrsUS$177.01k0.094%
$ 231.1k
Esther Martinborough
Independent Director3.1yrsUS$170.21k0.082%
$ 202.2k

3.3yrs

Average Tenure

62yo

Average Age

Experienced Board: CDXS's board of directors are considered experienced (3.3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.